NCT01980953 - A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Healthy Volunteer

Interventions

DRUG

GDC-0032 Phase III Tablet

Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.

DRUG

GDC-0032 Tablet

Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.

DRUG

GDC-0032 Capsule

Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.

Trial Locations (1)

Covance Research Unit - Dallas, Dallas